Cyclin A and Ki-67 with DNA content in benign and malignant prostatic epithelial lesions

Analytical and Quantitative Cytology and Histology

Volumn 23, Issue 3, 2001, Pages 229-237

  Mirtti, T ^a   Kallajoki, M ^a   Aaltonen, M ^a   Alanen, K ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Cyclin A; DNA; Image cytometry; Immunohistochemistry; Ki 67 antigen; Ploidies; Prostatic hyperplasia; Prostatic neoplasms

Indexed keywords

CYCLIN A; DNA; KI 67 ANTIGEN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BENIGN TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE CLASSIFICATION; DNA CONTENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE DISEASE; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

CYCLIN A; DIAGNOSIS, DIFFERENTIAL; DNA, NEOPLASM; HUMANS; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; PLOIDIES; PROSTATIC DISEASES; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034961392     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Common patterns of genetic evolution in human solid tumors
2. Assessing genetic markers of tumour progression in the context of intratumour heterogeneity
3. The prognostic significance of nuclear DNA content in prostatic carcinoma
4. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate
5. P53 expression, proliferation marker Ki-S5, DNA content and serum PSA: Possible biopotential markers in human prostatic cancer
6. Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma
7. Kip1 in normal, hyperplastic and neoplastic cells
8. Proliferating cell nuclear antigen/cyclin in incidental carcinoma of the prostate
9. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma
10. Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma
11. Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the proliferative cell fraction of human prostatic carcinoma
12. Expression of cell cycle-regulated proteins in prostate cancer
13. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)
14. The cell cycle
15. Expression of cyclin A and D proteins in prostate cancer and their relation to clinicopathological variables and patient survival
16. DNA-ploidy, G2M-fractions and prognosis of stages B and C prostate carcinoma
17. Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of the prostate
18. DNA in radical prostatectomy specimens: Prognostic value of tumor ploidy
19. Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade and age
20. Progression and survival in prostatic adenocarcinoma: A comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy
21. DNA ploidy by image analysis of individual foci of prostate cancer: A preliminary report
22. Grading of prostatic carcinoma
23. Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging
24. Pathology of adenocarcinoma of the prostate
25. Quantitative cytochemical aspects of combined Feulgen naphtol yellow S staining procedure for the simultaneous determination of nuclear and cytoplasmic protein and DNA in mammalian cells
26. Effect of DNA ploidy classification on prognosis in breast cancer
27. Image cytometry of breast carcinomas that are DNA diploid by flow cytometry: Time to revise the concept of DNA diploidy?
28. cdc2
29. DNA ploidy measurements in prostate cancer: Differences between image analysis and flow cytometry and clinical implications
30. Ploidy results in prostatic carcinoma vary with sampling method and with cytometric technique
31. Methodological aspects on flow cytometry and image cytometric nuclear DNA assessments in prostatic adenocarcinoma
32. DNA measurement on histologic slides: Does it work on human tissue?
33. Primary melanoma of the skin: Relationships of nuclear DNA content, nuclear morphometric variables, Clark level and tumor thickness
34. Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens
35. Breast carcinoma, intratumour heterogeneity and histological grading, using geostatistics